Vinblastine, Bleomycin, and Methotrexate Chemotherapy plus Irradiation for Patients with Early-Stage, Favorable Hodgkin Lymphoma: The Experience of the Gruppo Italiano Studio Linfomi

Cancer

Volumn 98, Issue 11, 2003, Pages 2393-2401

  Gobbi, Paolo G ^a   Broglia, Chiara ^a   Merli, Francesco ^b   Dell'Olio, Matteo ^c   Stelitano, Caterina ^d   Iannitto, Emilio ^e   Federico, Massimo ^f   Bertè, Raffaella ^g   Luisi, Dimitri ^h   Molica, Stefano ⁱ   Cavalli, Carla ^j   Dezza, Laura ^k   Ascari, Edoardo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Ematologia   (Italy)

^c Cura Caratt Sci Polic S Matteo   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g Ospedale Civile   (Italy)

^h SPIRITO SANTO HOSPITAL   (Italy)

ⁱ PUGLIESE CIACCIO HOSPITAL   (Italy)

^j Ospedale Civile   (Italy)

^k Ospedale Predabissi   (Italy)

more..

Author keywords

Chemotherapy; Hodgkin; Radiotherapy; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; METHOTREXATE; PREDNISONE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; LUNG; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; VINCRISTINE;

EID: 0344412951     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11807     Document Type: Article

References (22)

1. Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999;93:761-779.
2. Homing SJ, Hoppe RT, Hancock SL, et al. Vinblastine, bleomycin, and methotrexate: an effective adjuvant chemotherapy in favorable Hodgkin's disease. J Clin Oncol. 1988;6:1822-1831.
3. Nordijk E, Carde P, Mandard AM, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Group Pierre-et-Marie-Curie. Ann Oncol. 1994;5(Suppl 2)523-529.
4. Moody AM, Pratt J, Hudson GV, et al. British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical Stage IA and IIA Hodgkin's disease. Clin Oncol (R Coll Radiol). 2001;13:262-268.
5. Gobbi PG, Pieresca C, Frassoldati A, et al. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi experience. J Clin Oncol. 1996;14:527-533.
6. Lister TA, Crowther D, Sutcliff SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. J Clin Oncol. 1989;7:1630-1636.
7. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987;14:65-74.
8. DeVita VT Jr., Hubbard SM, Longo DL. The chemotherapy of lymphoma: looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1987;47:5810-5824.
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:129-137.
10. Armitage P, Berry G. Statistical methods in medical research (2nd edition). Oxford: Blackwell Scientific, 1987:296-357.
11. Dixon DO, McLauglin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987;5:1670-1672.
12. Carde P. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? Leuk Lymphoma. 1995;15:31-40.
13. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10:210-218.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
15. Bates NP, Williams MV, Bessell EM, et al. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical Stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study. J Clin Oncol. 1994;12:288-296.
16. Homing SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical Stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate and bleomycin chemotherapy and regional irradiation. J Clin Oncol. 1997;15:1736-1744.
17. Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologica. 2000;85:729-732.
18. Martinelli G, Cocorocchio E, Peccatori F, et al. Abstract CO-024 [abstract]. Haematologica. 2001;86(Suppl 10):19.
19. Kun LE, DeVita VT Jr., Young RC, et al. Treatment of Hodgkin's disease using intensive chemotherapy followed by irradiation. Int J Radiat Oncol Biol Phys. 1976;1:619-626.
20. Bonadonna G, Zucali R, De Lena M, et al. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Cancer Treat Rep. 1977;61:769-777.
21. Kaplan HS, Rosenberg SA. The management of Hodgkin's disease. Cancer. 1975;36:796-803.
22. Ginsberg SJ, Comis R. The pulmonary toxicity of antineoplastic agents. Semin Oncol. 1982;9:34-42.